ALEXION HEART DRUG FAILS IN TRIAL

A A

Alexion Pharmaceuticals has reported that its experimental drug failed to prolong survival in patients who had undergone angioplasty procedures to clear clogged coronary arteries.

The company said patients taking the drug, pexelizumab, did not achieve statistically significant reductions in mortality 30 days after undergoing the angioplasties in a late-stage trial.

The company, which is developing the drug with Procter & Gamble, said the negative results follow the medicine's earlier failure in a trial that involved patients undergoing coronary bypass graft surgery.